Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04362150 · ClinicalTrials.gov registry record

Long-term Impact of Infection With Novel Coronavirus (COVID-19)

A clinical trial of COVID, sponsored by University of California, San Francisco.

Recruiting
Registry status
800
Enrollment target
1
Study location

NCT04362150 is a study of COVID that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 800 participants, below the 2,546-participant average among 14 other COVID trials with a reported enrollment target (69% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04362150, a study of COVID, is actively recruiting participants, sponsored by University of California, San Francisco.

RECRUITING
Registry status
800 participants
Enrollment target
1
Study location

Study Summary

LIINC is a study of volunteers who were previously infected with SARS-CoV-2 (also known as novel coronavirus or COVID-19) who have recovered from acute infection. The study is designed to provide a specimen bank of samples with carefully characterized clinical data. LIINC specimens will be used to examine multiple questions involving the virologic, immunologic, and host factors involved in COVID-19, with a focus on understanding variability in the long-term immune response between individuals.

Conditions Studied

Study Locations (1)

California

  • Zuckerberg San Francisco General Hospital (ZSFG) - San Francisco

Trial Details

FieldValue
Enrollment Target 800 participants
Start Date 2020-04-21
Est. Completion 2030-12-31

What the Registry Record Tells You About NCT04362150

The ClinicalTrials.gov registry entry for NCT04362150 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 800 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,546-participant average among 14 other COVID trials with a reported enrollment target (69% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with COVID appearing as the primary indexed condition, and to 0 interventions.

NCT04362150 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT04362150 about?

NCT04362150 is a clinical study titled "Long-term Impact of Infection With Novel Coronavirus (COVID-19)". LIINC is a study of volunteers who were previously infected with SARS-CoV-2 (also known as novel coronavirus or COVID-19) who have recovered from acute infection. The study is designed to provide a specimen bank of samples with carefully characterized clinical data. LIINC specimens will be used to e...

What is the current status of trial NCT04362150?

This trial is currently recruiting. The enrollment target is 800 participants. The study started on 2020-04-21. Estimated completion is 2030-12-31.

What conditions does trial NCT04362150 study?

This clinical trial studies the following conditions: COVID.

Who is sponsoring clinical trial NCT04362150?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04362150 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for COVID

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.